 "Cipla takes majority stake in Ugandan firm")
Pharma giant Cipla has acquired a majority stake in Uganda’s Quality Chemical Industries (QCIL), with the acquisition of an additional 14.5 per cent stake for $15 million through its subsidiary, Meditab Holdings Ltd (MHL).
“MHL was earlier holding a 36.55 per cent stake in QCIL. MHL now holds 51.05 per cent stake in QCIL,” the company said.
Shares of Cipla closed at Rs 387, down 1.41 per cent on the BSE exchange.
QCIL’s mainly makes and sells anti-AIDS and anti-malarial drugs. It has a manufacturing facility approved by the World Healh Organization in Uganda.
“MHL was earlier holding a 36.55 per cent stake in QCIL. MHL now holds 51.05 per cent stake in QCIL,” the company said.
Shares of Cipla closed at Rs 387, down 1.41 per cent on the BSE exchange.
QCIL’s mainly makes and sells anti-AIDS and anti-malarial drugs. It has a manufacturing facility approved by the World Healh Organization in Uganda.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%